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PP2A and human therapyProtein phosphatase 2A (PP2A) is a large family of holoenzymes that comprises 1% of total cellular proteins
and accounts for the majority of Ser/Thr phosphatase activity in eukaryotic cells. Although initially viewed as
constitutive housekeeping enzymes, it is nowwell established that PP2A proteins represent a family of highly
and sophistically regulated phosphatases. The past decade, multiple complementary studies have improved
our knowledge about structural and functional regulation of PP2A holoenzymes. In this regard, after
summarizing major cellular regulation, this review will mainly focus on discussing a particulate biological
strategy, used by various viruses, which is based on the targeting of PP2A enzymes by viral proteins in order to
speciﬁcally deregulate, for their own beneﬁt, cellular pathways of their hosts. The impact of such PP2A
targeting for research in human diseases, and in further therapeutic developments, is also discussed.Curie 91 Boulevard de l'Hôpital
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
An estimated one third of the cellular proteins is reversibly
phosphorylated on speciﬁc serine/threonine (Ser/Thr) residues.
Reversible protein phosphorylation, a dynamic process controlled by
the coordinated action of phosphorylating (kinases) and depho-
sphorylating (phosphatases) enzymes, is a key regulatory mechanism
that regulates multiple intracellular pathways. There are many
different Ser/Thr-speciﬁc kinases, each of them being subjected to a
speciﬁc regulation, that phosphorylate Ser/Thr residues on speciﬁc
protein substrates. In contrast, to antagonize kinase activities through
speciﬁc dephosphorylation of Ser/Thr residues, cells used a very
limited number of phosphatase catalytic subunits that rely on speciﬁc
interactions with regulatory proteins to generate a large diversity of
phosphatase holoenzymes.
The Ser/Thr phosphatases were originally classiﬁed into type-1
(PP1) or type 2 (PP2), according to their substrate speciﬁcity and
sensitivity to pharmacological inhibitors. In addition type-2 phos-
phatases were subdivided into major classes, including PP2A,
calcium-dependent calcineurin (PP2B) and magnesium-dependentPP2C [1]. Today, based on sequence and structural homology of
catalytic subunits, and enzymatic mechanisms, Ser/Thr phospha-
tases are divided into two large families, known as PPP (Phospho-
Protein Phosphatases) and PPM (Protein Phosphatases Metal-
dependent). Moreover, other related PPP proteins, such as PP4,
PP5, PP6 and PP7, that occurred at low abundance and are expressed
in a tissue-and development-speciﬁc manner, have also been
characterized [2].
Numerous viruses ranging from DNA-Tumor viruses to retrovi-
ruses have developed sophisticated strategies in order to deregulate
cellular functions via PP2A. This review summarizes our recent
knowledge on cellular PP2A proteins and discusses the functional
relevance of interactions between PP2A and viral-proteins and their
impact on deregulation of cellular pathways. Starting from the
biological consequences of these interactions and their ability to
speciﬁcally target the deregulation of particular cellular pathways, we
also discuss how the mimicry of PP2A binding and viral proteins may
also serve to evolve new therapeutic developments.
2. Structure of cellular PP2A holoenzymes
PP2A refers to a large family of dimeric and heterotrimeric Ser/Thr
phosphatases that account for the majority of Ser/Thr phosphatase
activity in eukaryotic cells [3]. PP2AD, the PP2A core dimeric enzyme
comprises a 36 kDa catalytic PP2Ac (also called PPP2C) and a
structural A subunit, also known as PR65 or PPP2R1 (Fig. 1). In
Fig. 1. Structure and regulation of dimeric and trimeric cellular PP2A holoenzymes. A)
Three-dimentional crystal structure of a trimeric PP2A holoenzyme bound to
microcystin-LR (ref [175] see also ref [11] for recent published crystal structure of
the PP2A1 holoenzyme). The scaffold (Aα), catalytic (Cα), and regulatory B (Bα)
subunits are shown in blue violet, pink and green respectively. (B) Regulations of
dimeric and trimeric cellular PP2A holoenzymes: The catalytic subunit PP2Ac has never
been found as a free molecule, but is usually associated to the A structural subunit
constituting the dimeric core A/C (illustration is based on 2ie3.pdb structure) or,
alternatively, to mammalian a4 protein, an orthologue of the yeast Tap42 protein. The
binding of a structurally unrelated third variable (B/B′/B″/B‴’) subunit to PP2AD
generates the diversity of trimeric holoenzymes. Reversible methylation of PP2A-C
leu309 by leucine carboxyl methyltransferase (LCMT) and phosphatase methylesterase
(PME-1) regulates the binding of the third variable type B subunits. In addition binding
of the phosphatase regulator PTPA to the PP2A–PME-1 inactive complex, provokes a
conformational change leading to dissociation of PME-1 allowing the formation of
trimeric holoenzyme [161].
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expressed and two distinct genes encode closely related versions of
the PP2A A (Aα and Aβ) [4,5] and C (Cα and Cβ) subunits [6,7].
Cells contain a pool of dimeric PP2AD enzyme that can exist alone
[8] or also be associated with a third partner corresponding to a
variable “type B” subunits. PP2A B-type subunits contain a split A
subunit-binding domain allowing competition with other B-type
subunits for A subunit binding [9]. As illustrated in Fig. 1, four major
classes of “type B” subunits have been characterized and referred as B,
B′, B″, and B‴. In addition, each of the “type B” subunits of PP2A can
exist in several isoforms that potentially generate a multitude of
(NN75) holoenzyme compositions.3. Regulation of cellular PP2A holoenzymes
3.1. Regulation by B subunits
Regulation of PP2A primarily involves a combinatorial assembly of
type-B subunits with PP2AD core enzyme and, in addition, PP2A
activity, substrate speciﬁcity and cellular localization depend on the
nature of a B subunit. For example, in contrast to dimeric PP2AD, the
trimeric ABαC holoenzyme efﬁciently dephosphorylates the brain
microtubule-associated protein Tau, suggesting that Tau-dephos-
phorylation is critically regulated by speciﬁc Bα targeting of the
trimeric holoenzyme [10,11]. However, as illustrated in Fig. 1, in
addition to type-B subunits both speciﬁc cellular regulators and post-
translational modiﬁcation also regulate PP2A activity. For example
binding of α4 protein (Tap42 in yeast) to the PP2A catalytic subunit
generates a speciﬁc heterodimer [12]. This dimeric Tap42/α4-PP2A
phosphatase can repress apoptosis in mammalian cells through
negative regulation of c-Jun and p53 [13].3.2. Regulation by post-translational modiﬁcations of the catalytic
subunit
Methylation and phosphorylation, two distinct post-translational
modiﬁcations of the PP2Ac C-terminus 304-TPDYFL-309 sequence,
regulate subunit composition of PP2A as well as catalytic activity and
substrate speciﬁcity of holoenzymes. PP2A phosphorylation on both
Thr and Tyr residues inactivates PP2A and its reactivation requires
intramolecular autodephosphorylation catalyzed by PP2A [14,15].
Thr304 phosphorylation is dependant on an autophosphorylation-
activated protein kinase [16]. Tyr307 phosphorylation was found in
ﬁbroblasts overexpressing pp60 v-src and in chronic myelogenous
leukemia cells that overexpress the PP2A inhibitor called SET or I2PP2A
[17].
Reversible methylation regulates the binding of the third variable
type B subunit [18]. The free carboxyl group of the C-terminal Leu309
residue is methylated by the S-adenosylmethionine-dependent
LCMT1 (leucine carboxyl methyltransferase 1) [19,20]. Demethylation
is catalyzed by a speciﬁc phosphatase methylesterase, PME-1 [21,22].3.3. Regulation by PTPA
The Phosphotyrosyl phosphatase activator (PTPA) was initially
considered as a B subunit that interacted with AC core to speciﬁcally
activate a phosphotyrosyl phosphatase (PTPase) activity [23]. How-
ever later ﬁndings indicate that PTPA, also renamed PP2A Phosphatase
Activator, functions as a chaperone able to reactivate the Ser/Thr
phosphatase activity of inactive PP2A [24,25]. Indeed, ATP–Mg2+
stimulated peptidyl prolyl cis/trans isomerase activity of PTPA is
required to reactivate inactive PP2A and PTPA binding to the PP2A-
PME–1 inactive complex, provokes a conformational change leading
to dissociation of PME-1 that permits the formation of an active
trimeric holoenzyme [26].3.4. Cellular interacting proteins
In addition to type-B subunits a large and still growing number of
cellular proteins can interact with one or more PP2A subunits or can
associate with a speciﬁc holoenzyme. As illustrated in Table 1 [10,27–
85], several cellular partners including protein kinases, cytoskeleton,
structural, regulatory proteins such as receptors or transcription
factors controlling major intracellular pathways (Hox, Wnt, Ras,…),
can form stable active complexes with PP2A. The formation of such
complexes represents a major way to regulate PP2A activity and
PP2A-mediated intracellular pathways.
Table 1
Cellular PP2A interacting proteins. Studies in the past decade allowed us to identify a plethora of cellular PP2A-interacting partners that deﬁne paradigms towards multiple
PP2A-mediated biological processes.
Protein Effects Ref.
[PP2A]–[Protein–Kinases]
Aurora-A Binding to PP2Ac is involved in Aurora degradation during mitosis. [27]
CaM Kinase IV Binds PP2A1 holoenzyme. Associates and regulates CaM Kinase IV. [28]
Casein kinase 2 (CK2) Binds dimeric PP2A/C. Involved in Ras/raf/Mapk pathway. [29]
JAK2 Interacts with PP2Ac (probably through dimeric AC) uppon IL-11
induction in 3T3-L1 adipocyte cells.
[30]
KSR (kinase suppressor of Raf) Binds to dimeric (non stimulated cells) or trimeric PP2A (stimulated cells). [31]
PAK1 (P21 activated kinase) PAK1 is a substrate for PP2A1 in a preexisting Kinase–phosphatase complex. [32]
P70-S6kinase P70-S6kinase is a substrate for PP2A1 in a preexisting Kinase–phosphatase complex. [33]
PKCα PP2Ac and PKCα are physically associated in Mast cells. PP2A controls
PKCα phosphorylation.
[34]
PKCδ PKCδ physically associates with the PP2Ac to increase its phosphatase activity. [35]
PKR Interacts with B56 subunit of trimeric PP2A and regulates the activity of the
translation initiation factor eIF4.
[36]
RAF-1 Interacts with dimeric core A/C to regulate RAF/Mek pathway. [37]
Src Binds to dimeric core A/C. PP2A inhibits src activity. [38]
[PP2A]–[Mitosis/cell cycle/cytoskeleton]
Cas (p130 Crk-associated Src substrate) Binds dimeric core A/C. Involved in cell cycle speciﬁc dephosphorylation of Cas. [39]
Cdc6 Binds trimeric A/C/PR48 holoenzyme and is involved in cell cycle regulation. [40]
Cdc25c Binds A/C/B56δ holoenzyme and is involved in mitosis regulation. [41]
CG-NAP (AKAP 350) Binds PR130 subunit of trimeric A/C/PR130 holoenzyme, involved in cell cycle and
centrome dynamic regulation.
[42]
Cyclin G1 P53-dependent binding to PP2A-B′ subunit. [43]
Cyclin G2 Binds to B′ subunits and provokes G1/S cell cycle arrest. [44]
DNA polymerase α primase (Pol-Prim) Cell cycle-dependent association of demethylated dimeric core A/C with Pol-Prim. [45]
HOX 11 Binds to C-subunit to disrupt a G2/M cell cycle checkpoint. [46]
P107 R3/PR59 subunit of trimeric PP2A binds P107 but not related pRB protein. Involved
in G1 cell cycle arrest.
[47]
NF-L, NF-M, and NF-H
(Neuroﬁlament proteins)
PP2A1 subunits associate with NF proteins. PP2A mediated dephosphorylation of NF
proteins promotes assembly of NF proteins.
[48,49]
Vimentin Binds the Bα subunit and is dephosphorylated by PP2A1 in Hs68 ﬁbroblasts. [50]
Shugoshin Binds to trimeric AB′C holoenzyme to regulate centromeric protection of cohesion
during meiosis. The Shugoshins-PP2A complex dephosphorylates cohesin to
prevent cleavage by separase during meiosis I.
[51,52]
Greatwall Gwl is a promitotic kinase that phosphorylates α-endosulﬁne (Ensa).
Ensa suppresses antimitotic activity the trimeric PP2A-B55δ holoenzyme.
[53]
[PP2A]–[Receptor/transporter/membrane]
β-adrenergic receptor Binds PP2A1 holoenzyme. Regulates receptor resensitization and recycling to
plasma membrane.
[54]
Estrogen receptor α
(Erα)
Binds to C subunit. PP2Ac controls the phosphorylation of Erα. [55]
NMDA receptor (NMDAR) PP2Acβ associates with NR3A subunit of NMDAR. NMDAR stimulation regulates
both PP2A activity and PP2A association with the receptor.
[56]
Shc adaptor protein PP2A associates with the PTB domain of Shc in the basal state and dissociates in
response to growth factors (insulin and EGF).
[57]
Amine transporters Binds PP2Ac. Regulates heteromeric assemblies involving biogenic amine in presynaptic
transporter proteins.
[58]
E-cadherin Binds PP2Ac. Required for stabilization of E-cadherin/β-catenin complexes at the
plasma membrane.
[59]
Class C L-type calcium
chanel
Binds dimeric core A/C. Antagonizes PKA-mediated chanel phosphorylation. [60]
STAT5 Binds to PP2Ac upon IL-3 stimulation of in myeloid progenitors. PP2A plays a
negative regulatory role in regulating the IL-3 signaling pathway via formation of
complexes with JAK2 and Stat5.
[61]
[PP2A]–[Apoptosis/cell activation/diseases]
Bcl-2 Bcl-2 interacts with PP2A. PP2A dephosphorylates Bcl-2. [62]
Caspase 3 Binds and cleaves structural Aα subunit. Stimulates PP2A activity and apoptosis
induced by anti-Fas antibody.
[63]
CD28 and CTLA-4
receptors
Two T lymphocyte cell surface receptors bind trimeric PP2A through their short
intracytoplasmic domain.
[64]
HRX Binds PP2A through I2PP2A involved in acute leukemias. [65]
I2PP2A (SET) Speciﬁc PP2A inhibitor involved in acute myeloid leukemiogenesis. [66]
I1PP2A (PHAP1, mapmodulin) Potent heat stable Inhibitor of PP2A. [67]
Tau Binds to Bα subunit of trimeric PP2A1 holoenzyme. Tau dephosphorylation promotes
microtubule binding and stabilization. Hyperphosphorylated tau provokes neuroﬁbrillary
tangles in brains of patients with Alzheimer's disease (AD) and related tauopathies.
[10,68]
CIP2A Human oncoprotein that interacts with PP2A-A subunit and inhibits PP2A-mediated
dephosphorylation and subsequent proteolytic degradation of Myc protein.
[69]
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Table 1 (continued)
Protein Effects Ref.
[PP2A]–[Transcription-protein synthesis]
TRIP-Br1 Binds to Bα subunit of trimeric PP2A1 holoenzyme and regulates transcription and
cell cycle progression.
[70]
eRF1 Binds to C subunit of dimeric core A/C. Regulates termination of protein synthesis. [71]
IKK γ subunit (also named NEMO) Binding to PP2Ac is involved in the regulation of I-κB kinase. [72]
RelA (member of the NF-κB family of
transcription factors)
Binds the A subunit of dimeric core A/C. PP2A dephosphorylates RelA. [73]
SP1 Interacts with PP2Ac in T cells and remains dephosphorylated during cell cycle. [74,75]
Heat Shock transcription
factor 2
HSF2 binds to structural A subunit and competes with binding of C-subunit. [76]
Carmal1 Binds structural Aα subunit (dimeric core A/C) involved in T-cell activation. [77]
[PP2A]–[Hox/Wnt/Alpha4/Ca2+ pathways]
Adenomatous Polyposis
Coli (APC)
Binds B56 subunit. Regulates Wnt signaling pathway. [78]
Axin Binds C subunit. Regulates Wnt signaling pathway. [79]
Mid1 Interacts with α4 protein in a complex with the PP2Ac. Involved in ubiquitin-dependent regulation of
microtubule-associated phosphatase 2A.
[80]
SCR (sex Combs Reduced) homologouus to human
HOX5 and HOX6
Binds B56 subunit of trimeric Holoenzyme. PP2A positively modulate homeotic function. [81]
Striatin and S/G(2) nuclear autoantigen (SG2NA), Two highly related WD40 repeat proteins that bind dimeric core A/C. May function as scaffolding proteins type B
proteins involved in Ca2+-dependent signal transduction pathways.
[82]
Tap42/α4 Interacts with PP2Ac in Tor–Rapamycin pathway. Mammalian homolog α4 involved in B cell activation. [83]
alpha4-b Interacts with PP2Ac.alpha4-related gene (66% identity in amino-acid sequence) expressed selectively in the
brain and testis.
[84]
Type 2A-interacting protein (TIP) Binds PP2Ac and inhibits PP2A activity. Expressed in human cancer cells. [85]
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Viral proteins encoded by different viruses can form stable
complexes with PP2A holoenzymes or, with cellular PP2A interacting
proteins, in order to selectively subvert important cellular pathways.
The functional effects of PP2A association with a viral protein are
critical for the accomplishment of viral life cycle. As illustrated in
Table 2, and in Ref. [86–102], the diversity of already identiﬁed PP2A-
associated viral proteins suggests a widespread viral strategy that can
be schematized in the following points.4.1. Viral oncoproteins encoded by DNA/RNA tumor viruses can interact
with PP2A to activate pathways involved in cell transformation and in
diseases
PP2A is a tumor suppressor gene and pharmacological inhibitors of
PP2A such as microcystin and okadaic acid act as potent tumor
promoters [103]. PP2A has been implicated in the regulation of
several major signaling pathways, including Wnt, PI3K/Akt, MAPK,
and c-Myc, that result in cell transformation [104]. Consistently,
inactivating mutations of PP2A A subunits have been detected in
human cancers [105–108] and the inactivation of these subunits
contributes to cell transformation [109,110]. In this regard some DNA
tumor viruses of the papovae family encode small proteins (around
100 aa residues), such as small t antigens and polyomavirus middle T,
that are found associated with dimeric core AC in infected or
transfected cells and behaves as potent oncogenes [111]. Studies of
the transformation induced by the DNA tumor Simian virus 40 (SV40)
or Murine polyoma virus (Py) allowed a better understanding of the
pathways involved in cancers [112].
Biochemical, mutational andmore recently structural experiments
conﬁrm that SV40 small t directly interacts with the PP2A scaffolding
A subunit and regulates PP2A activity by displacing regulatory B
subunits from the A subunit [113,114]. Functional experiments have
also clearly demonstrated that the binding of SV40 small t to PP2A is a
prerequisite for its cell transformation occurrence [115,116]. In
addition, as illustrated in Fig. 2 it has been demonstrated that SV40
small t inhibits PP2A through a speciﬁc targeting and displacing ofvariable subunits (B′/B56/PR61, B56γ), resulting in activation of PI3K/
Akt, Wnt, and c-Myc pathways involved in tumors [117].
Py middle T-antigen (PyMT) associates with cell membranes and
provokes tumors by mimicking an activated growth factor receptor
[118]. The interaction between PP2A dimeric core enzyme and PyMT
is required for the subsequent assembly of the transformation-
competent PyMT complex that includes pp60c-src and phosphatidy-
linositol 3-kinase [118,119], in that later case PP2A associated to PyMT
carries a tyr-phosphatase activity sensitive to okadaic acid [96].
Recent discovery of human polyomaviruses has yield a new
interest in the role played by polyomaviridae encoded proteins in
human disease. Merkel cell polyomavirus (MCV) is the etiological
agent of human Merkel cell carcinomas, a highly aggressive skin
cancer [120]. PP2A targeting by MCV small T-Antigen was found to be
required for enhanced viral replication [95].
JC virus (JCV) infects oligodendrocytes and is the etiological agent
of a progressive multifocal leukoencephalopathy (PML), a rare
demyelinating disease that affects elderly or immunocompromised
patients. Two small JCV virally encoded proteins, agnoprotein and
small t antigen can interact with PP2A. Agnoprotein phosphorylation,
which is antagonistically controlled by PKC and PP2A, is essential for
the viral life cycle. The PP2A inhibition by small t antigen inhibits the
dephosphorylation of agnoprotein by PP2A. In addition, interplay
between PP2A with agnoprotein and small t antigen could be
important for the PML disease progression [91].
BK virus (BKV) infects kidney epithelial cells and is the etiological
agent of a polyomavirus-associated nephropathy (PVN) that occa-
sionally develops in renal transplant [121]. Based on the inactivation
of the functions of the tumor suppressor mediated by proteins p53
and pRB family, a role of BKV in oncogenesis processes has been
suggested [121]. Moreover the BKV small t antigen binds to the A/C
PP2A core subunits suggesting a contribution of PP2A in the
underlying mechanism of cell transformation [122].
Human papillomaviruses (HPV), a major etiologic agent of cervical
cancer [123] encodeHPV-E7, a small oncogenic protein of approximately
100 amino acids, that regulates viral replication and is involved in
infectedhost cell transformation [124]. It has been recently reported that
binding of HPV-E7 to PP2A dimeric A/C core leads to the constitutive
activation of the PI3K/PKB a survival/transforming pathway [94].
Cell effectors
(SET-I2PP2A/ α4…)
T
U
M
O
R
S
CIP2A
A
C
B Subunit
Deregulation
A
RAS
PI3K/Akt/
Mek
pathways
Wnt
pathway
A
B56/
PR61γ
A
Small t
Small t 
C C
B56/
PR61γ
-c-Myc + 
-other  transcription Factors
(CREB-AP1-SP1-E2F-NF-κB)
B
A mutations
TUMORS
Methyl regulators
(PME1/PPM1)
Activation of survival &transforming pathways
Fig. 2. PP2A inhibition can induce oncogenic pathways. A) Several mechanisms can
regulate transforming pathways through PP2A: Mutations in structural A subunit that
decrease PP2A activity have been characterized in several human cancers [106].
Truncation of PR61/B′γ provokes radio-resistance and increases metastasis [161].
Deregulation PP2A methylation [151] and upregulation of oncogenic PP2A inhibitors
such as SET, CIP2A or α4 [154–156]. B) PP2A and SV40 small t: an example of how viral
deregulation of PP2A-mediated intracellular pathways can lead to cell transformation.
SV40 small t displaces some regulatory subunits to activate transforming pathways.
Interestingly the suppression of PR61/B′γ subunit mimics the transforming effect of
SV40 small t [117].
Table 2
Viral PP2A interacting proteins.
Virus Protein Effects Ref.
Adenovirus Adenovirus
E4orf4 protein
Binds to AC–R2 complex; formation of
complex required for E4orf4-
mediated apoptosis.
[86,87]
BKV BKV small t
antigen
Binds A and C subunits. Possible role
in oncogenesis.
[88]
EBV EBNA-LP Truncated EBNA-LP interacts with
PP2Ac to inhibit apoptosis. A possible
mechanism for EBV persistence.
[89]
JCV JCV agnoprotein Binds PP2Ac. Co-precipitates with
small t Antigen and PP2A.
[90]
JCV JCV small t
antigen
May bind dimeric core A/C dimer. Co-
precipitates with PP2Ac and
agnoprotein and inhibits PP2A-
mediated dephosphorylation of
agnoprotein.
[91]
HCV HCV NS5A Binds dimeric core A/C to up-regulate
PP2A activity to inhibits of IFN-α
signaling.
[92]
HIV-1 HIV-1 Vpr Binds A subunit and PP2A1
holoenzyme. Role in cell cycle arrest
and apoptosis.
[93]
HPV HPV-E7 Binds dimeric core A/C and inhibit
Akt/PKB dephosphorylation.
[94]
MCV MCV small t
antigen
Binding to PP2A allows optimal
replication.
[95]
Polyoma Polyomavirus
middle tumor
antigen
Binds to AC dimer; increases tyrosine
phosphatase activity of PP2A.
[96,97]
Polyoma Polyomavirus
small tumor
antigen
Binds to dimeric core A/C allowing
activation of the c-src tyrosine kinase
and phosphatidylinositol 3-that
facilitates host-cell transformation.
[97,98]
SV40 SV40 small
tumor antigen
Binds to AC dimer; displaces R2
subunits; inhibits PP2A activity.
[99]
HTLV-1 Tax The human T-lymphotropic retrovirus
type-I transactivator Tax interacts via
a tripartite protein interaction that
also involves IKKγ. The association of
Tax with this complex inhibits PP2A
activity maintaining Tax-PP2A-IKK in
an active state.
[100,101]
West Nile West Nile virus
capsid protein
(WNVC)
Binds I2 PP2A to increase PP2A activity. [102]
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agent of human B-cell cancers, including Burkitt's lymphoma (BL),
Hodgkin's lymphoma, and in immunocompromised patients induces
lymphoproliferation [125]. The EBV-encoded leader protein (EBNA-
LP) is one of the six virally encoded nuclear antigens that have been
involved in EBV-induced B-cell transformation. Interestingly, Garibal
et al., [89] have recently proposed amechanism for EBV persistence, in
infected cells, based on the inhibition of PP2A-mediated apoptotic
pathway resulting from the binding of EBNA-LP with PP2Ac.
4.2. Adenoviral protein E4orf4 can interact with PP2A1 to induce
apoptosis
Adenovirus early region 4 open reading frame 4 (E4orf4) is an
early viral gene transcribed from the E4 promoter of human
adenoviruses. The small 114-residue E4orf4 protein is a highly
multifunctional viral regulator that persists during infection [126].
E4orf4 counteracts the effect of oncogenic viral protein E1A, down
regulates cellular transcription factors (AP1, E2F) and also negatively
regulates expression of the E4 promoter [127]. Interestingly during
early steps of infection the products of the viral gene (E1) (E1B55K
and E1B19K) inactivate p53 and prevent activation of the apoptotic
machinery. Later during the viral replication phase, the virus evolved
a p53-independent apoptotic process that could allow the dissemi-nation of its progeny. E4orf4 protein induces this process by
interacting with the regulatory Bα subunit of trimeric PP2A1
holoenzyme in infected or transformed cells but not in normal
human primary cells [87,128]. This p53 independent cell death
mediated by E4Orf4 resembles apoptosis in some human cancer cell
lines [129,130]. However other reports suggest that E4Orf4 may
inducemultiple death processes, depending on the physiological state
or type of cell. For example in human H1299 lung carcinoma cells, cell
death is caspase independent and appears to occur by mitotic
catastrophe following mitotic arrest [131,132]. Recent studies have
reported that E4orf4 binding reduced the activity of B55 containing
PP2A holoenzymes suggesting that E4orf4 toxicity may result from
the failure to dephosphorylate substrates involved in cell cycle
progression [131].
4.3. Flaviviral proteins interact with PP2A partners to upregulate PP2A
activity and to deregulate speciﬁc PP2A-mediated pathways
Hepatitis C virus (HCV), a small hepatotropic virus classiﬁed within
the Flaviviridae family, is themajor etiological agent of chronic hepatitis
which often causes two major chronic liver diseases: cirrhosis and
hepatocellular carcinoma [133]. The HCV-encoded non-structural
protein NS5A is a multifunctional serine phosphoprotein of 56–
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pathogenesis [134]. Recent work indicates that NS5A is a new type B
PP2A subunit that speciﬁcally interacts in vivo and in vitrowith PP2AA/
C core to up-regulate PP2Aactivity [92]. Up-regulation of PP2A increases
NS3 helicase activity and inhibits of IFN-α-induced Jak-STAT signaling,
two events associated to efﬁcient HCV replication [135].
West Nile virus (WNV), another virus of the Flaviviridae family, can
cause fatal neurological diseases [136]. WNV capsid protein (WNVC)
is a pathogenic determinant and the non-structural functions of this
protein involve speciﬁc interactions with host cell-encoded proteins.
In this regard, WNVC interaction with the host cell-encoded
phosphatase inhibitor I2PP2A, up regulates PP2A activity. WNVC-
induced up regulation of PP2A, is also involved in down regulation of
AP1 activity, and could eventually play a role in virus-induced
neurodegeneration [102].
4.4. Viral proteins encoded by retroviruses interact with PP2A and can
deregulate cell cycle and cell survival
Human T-lymphotropic virus type I (HTLV-1) is the etiological
agent of adult T-cell leukemia/lymphoma (ATL) [137]. The viral
transactivator/oncoprotein Tax, which regulates viral replication, is a
potent constitutive activator of NF-κB and is also critically required to
deregulate cell cycle and to initiate cell transformation. The holo-IκB
kinase (IKK) comprises two catalytic subunits, IKKα and IKKβ,
associated with a regulatory subunit, IKKγ/NEMO (NF-κB essential
modulator) regulates NF-κB activity [138]. IKK binds PP2A and via a
tripartite protein–protein interaction, Tax, IKKγ/NEMO, and PP2A
form a stable ternary complex [100]. PP2A inhibition by NEMO-bound
Tax maintains IKK in the phosphorylated/active state that is required
for phosphorylation/degradation of I-κB and subsequent activation of
NF-κB [100,139].
4.5. Tat and Vpr, two viral proteins encoded by human
immunodeﬁciency virus type 1 (HIV-1) interfere with PP2A pathways
HIV-1, a retrovirus of the lentivirus family, is the etiologic agent of
AIDS. HIV-1 transactivator Tat (HIV-1 Tat) is a small regulatory
protein, containing between 86 and 101 residues, that plays a pivotal
role in both viral replication and pathogenesis [140]. Interestingly
HIV-1 Tat modulates the expression of several cellular genes and
displays pro-apoptotic properties. Moreover, Tat association with the
promoters of PPP2R1B (structural subunit Aβ) and PPP2R5E (regu-
latory subunit B′ε) activates their transcription resulting in over
expression of PP2A subunits and up regulation of PP2A activity in
lymphocytes. These results suggest that the increased PP2A-activity
induced by Tat could participate to Tat-mediated apoptotic mecha-
nism [141].
HIV-1 Vpr is a small virally encoded 14 kDa accessory virion-
associated protein containing 96 residues that performs multiple
functions in vitro and plays an important role in viral pathogenesis
[142]. Similarly to HIV-1 Tat, HIV-1 Vpr is also a cell penetrating
protein that can display pro-apoptotic properties [142]. Interestingly
soluble entire protein has been identiﬁed in the serum and
cerebrospinal ﬂuid of HIV-1 infected individuals suggesting that Vpr
could penetrate into cells acting by a bystander effect in non infected
cells [143]. It has been ﬁrstly reported that Vpr induces cell cycle G2
arrest by interfering with the PP2A activities [144]. In addition we
have recently demonstrated that the non helical but ﬂexible C-
terminal domain Vpr77–92 originated from HIV-1 89.6 isolate, but not
from NL4.3 isolate, interacts with the A structural subunit of PP2A1
holoenzyme to trigger cell transducing and apoptotic effects. Mutation
experiments and comparative studies of HIV-1 89.6 Vpr77–92
domain in homologous and the routinely used NL4.3 strain, suggest
that sequence variability within Vpr77–92 sequences might regulate
the functional activities of the domain, including PP2A1 bindingcapacity and apoptotic properties [93]. In conclusion PP2A targeting by
viral proteins can deregulate proliferative and survival pathways.
HPV-E7, HTLV Tax and SV40 T antigens interact with PP2A to activate
survival pathways and to promote cell proliferation and cell
transformation. In contrast adenoviral E4Orf4 and HIV-1 Vpr interact
with PP2A to induce apoptosis and cell cycle arrest [132,142,145].
4.6. Viral complementary strategies to deregulate PP2A
Deregulation of PP2A activity in the absence of characterized
virally-encoded PP2A interacting proteins also exists in infected cells.
For instance, human cytomegalovirus (CMV), an Herpesviridae that
infects more than 50% population in western countries and can cause
congenital malformation, carries a cellular PP2A holoenzyme proba-
bly involved in early cellular phosphorylation shut off [146]. Hepatitis
B virus (HBV), a human hepadnavirus that causes acute and chronic
hepatitis associated with hepatocarcinogenesis, also induces a
signiﬁcant up-regulation of PP2Ac that correlates to inhibition of
IFN-α signaling [147].
5. PP2A: viruses and human diseases
5.1. PP2A dysfunction and human diseases
Consistently with a key role of PP2A in the control of multiple
cellular processes, a deregulation of some PP2A-regulated signaling
pathways, such as the PI3K/Akt survival pathways, can be associated
with several major human diseases including diabetes/obesity
[148,149], cancer [118] and neurodegeneration [150]. Interestingly,
as illustrated in Fig. 2A, several mechanisms involved in PP2A
dysfunction such as genetic alterations of A PP2A subunit [104],
deregulation of PP2Ac methylation [151] or over-expression of
endogenous cellular proteins [69] can lead to human diseases.
Concerning cancer, several endogenous PP2A inhibitor proteins
have been recently involved in human malignancies. In this regard,
the human oncoprotein named Cancerous Inhibitor of PP2A (CIP2A) is
a speciﬁc PP2A inhibitor which is over expressed in several types of
human cancer tissues and prevents PP2A-mediated degradation of c-
Myc protein [69,152–154]. CIP2A expression is also upregulated by
bacterial oncoprotein CagA, which is produced by Helicobacter pylori,
an etiologic factor of duodenal and stomach ulcers, and gastric cancer
[155]. Furthermore, upregulation of SET/I2PP2A, by the BCR/ABL
oncogene contributes to leukemogenesis [17]. In addition to SET/
I2PP2A and CIP2A, other endogenous proteins were found to inhibit
PP2A activity in cancer cells. For example, a recent study by Chen et al.
[156] indicates that upregulation of α4 in several types of primary
human cancers contributes to cell transformation.
In the case of neurodegenerative diseases, the aberrant hyperpho-
sphorylation of Tau protein, leading to neuroﬁbrillary destabilization
is one of the hallmarks of tauopathies including Alzheimer disease
[157]. It has been clearly established that such abnormal hyperpho-
sphorylated tau can result from speciﬁc PP2A1 deregulation in
response to upregulation of endogenous inhibitors [158] or to
inhibition of PP2Ac carboxy-methylation [159].
5.2. Exploration of PP2A dysfunction and viral proteins: lessons from
PP2A-pathways involved in human diseases
Viruses represent simple genetic tools that encode a limited
number of proteins able to target critical cellular players such as PP2A.
The two last decades multiple studies of the functional interaction of
diverse viral proteins with PP2A allowed us to identify key pathways
for viral biology that also play a role in human diseases such as
spontaneously arising cancers or neurodegenerative disorders. In-
deed, PP2A appears as a privileged target for proteins encoded by
some DNA/RNA viruses or retroviruses such as HIV-1. For example,
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SV40 small t, have allowed the better understanding of several
pathways involving PP2A inhibition and cell transformation (for
illustration see Fig. 2B and reviews [160,161]). Alternatively, studies
of pro-apoptotic PP2A-interacting and virally-encoded proteins, such
as adenoviral E4orf4 or HIV-1 Vpr proteins, provide new insights in
PP2A-mediated apoptotic pathways.
Concerning E4orf4, a toxic protein that could facilitate release of
viral progeny, its ectopic expression in cultured human cells
speciﬁcally induces a PP2A1-dependent and p53-independent cell
death in transformed or in tumor cells but not in healthy cells
[162,163]. These results clearly suggest that reproducing, or mimick-
ing, the anti-cancer effects resulting from PP2A1-E4orf4 interaction
could be a promising strategy for the development of new cancer
therapies. In this regard, direct electroporation of E4orf4 DNA
provoked growth inhibition of murine B16 tumors. However this
effect only occurs during the treatment, suggesting that electroporat-
ing gene transfer is inefﬁcient to obtain a permanent therapeutic
effect [164].
In the case of HIV-1 Vpr, this protein can induce apoptosis in
infected and non infected cells, and can also cause in vivo
neurodegeneration [165]. Interestingly, results by Godet et al. [93]
suggest that polymorphism in PP2A1 binding region located in the C-
terminal sequence of Vpr proteins could play a role in Vpr-mediated
and AIDS progression, including neurodegeneration. In this regard, it
is noteworthy that WNVC and Vpr, two distinct viral proteins that
bind PP2A [93,102], may represent molecular tools for neurodegen-
eration studies. Furthermore, in addition to studies concerning
neurological disorders, Vpr has also already been proposed as a
promising agent for cancer therapy [166].
5.3. PP2A, viral proteins and drug therapy: anticipated outcomes
PP2A, a key player in the pathogenesis of important human
diseases such as cancer or neurodegenerative disorders, is also a
potential key target for diagnostic and therapeutic developments. This
review intends to illustrate how PP2A inhibition by viral or cellular
oncogenic proteins, activates survival tumor pathways (Fig. 2 and refs.
[160,161]) or provokes neurodegeneration through hyperphosphor-
ylation of Tau protein [158]. We can speculate that cancer-associated
mutations of the structural A subunit, that inhibit PP2A activity, could
also be associated to tauopathies. More generally we can propose that
genetic approaches, such as a micro-array based technology, might be
used for family comparisons in order to study the association of a
polymorphism in PP2A1 subunits, including the A structural subunit,
with susceptibility to Alzheimer disease and tauopathies. In contrast
to PP2A inhibition, activation of PP2A1 holoenzyme by E4orf4
provokes apoptosis in tumor cells. It has been proposed that the
introduction of the FTY720, a small immunosuppressant molecule
designed for organ transplantation that activates PP2A, could be used
in the treatment of myelogenous leukemia [167,168]. Indeed,
pharmacological utilization of PP2A as drug target in clinical studies
was initially based on the use of cantharidin and fostriecin, two
natural antitumor small molecules that speciﬁcally bind and inhibit
PP2A catalytic subunits [169,170]. More recently FTY720, has been
used in phase III clinical trials for multiple sclerosis [171]. It is
noteworthy that a speciﬁc PP2A inhibition by SV40 small t protein
counteracts the FTY720-mediated activation of PP2A that inactivates
PI3K/Akt survival pathway, by preventing Akt dephosphorylation
[172]. These results suggest that to achieve therapeutic beneﬁts and to
antagonize PP2A targeting by viral, or by cellular, oncogenic proteins,
efforts are needed to design, or to discover, new molecular
competitors with high afﬁnity for PP2A. Indeed various studies,
using small-molecules or peptide antagonists, have previously
provided evidence for the feasibility of targeting PP2A-complexes
for drug development (for review see [173]). In this regard, tospeciﬁcally deregulate intra-cellular pathways controlled by PP1/
PP2A proteins, we previously validated and published an approach,
named Drug Phosphatase Technology (DPT). This approach is based
on the design of cell penetrating peptides mimicking PP1/PP2A-
interacting motifs that disrupt or modulate speciﬁcally phosphatase-
mediated pathways [174]. Interestingly, a penetrating peptide named
DPT-5 with a short sequence deduced from human CD28 that,
similarly to E4orf4 interacts with the PP2A1 Bα subunit, provokes
apoptosis in HeLa cells [174]. Furthermore we have also recently
found that a PP2A1 binding and cell penetrating sequence, deduced
from canine adenovirus E4orf4, induces apoptosis in tumor cells
(Galioot et al. in preparation).
In conclusion, the emerging wealth of functional data from viral
proteins improved our knowledge of PP2A-pathways involved in
human diseases. While DNA tumor viruses teach us how to activate
transforming pathways through inhibiting PP2A, others such as
adenoviruses or HIV-1 tell us how to inhibit survival pathways
through activating PP2A. The dissection of these opposite pathways
and the design of appropriate PP2A competitors that could deregulate
viral and pathogenic effects controlled by PP2A is clearly a challenging
question for future treatments.Acknowledgements
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